Brief: 20/20 Biolabs Launches Onetest For Longevity Blood Test And Chronic Disease Risk Assessment
25/02/2026 13:41
Feb 25 (Reuters) - 20/20 Biolabs Inc AIDX.O: 20/20 BIOLABS LAUNCHES ONETEST FOR LONGEVITY BLOOD TEST AND CHRONIC DISEASE RISK ASSESSMENT AND MANAGEMENT SOLUTION BUILT WITH IBM AI CAPABILITIES Source text: ID:nGNX14tzmP Further company coverage: AIDX.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on 20/20 Biolabs
See all newsBrief: Averin Capital Acquisition Corp. Announces The Separate Trading Of Its Class A Ordinary Shares And Warrants, Commencing April 10, 2026
Brief: 20/20 Biolabs Launches Onetest For Longevity Blood Test And Chronic Disease Risk Assessment
NASDAQ RESUMED AT 11:46 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:41 AM
NASDAQ RESUMED AT 10:01 AM